| Literature DB >> 35884233 |
Michela Galgano1, Paolo Capozza1, Francesco Pellegrini1, Marco Cordisco1, Alessio Sposato1, Sabina Sblano2, Michele Camero1, Gianvito Lanave1, Giuseppe Fracchiolla2, Marialaura Corrente1, Francesco Cirone1, Adriana Trotta1, Maria Tempesta1, Domenico Buonavoglia1, Annamaria Pratelli1.
Abstract
The spread of extended-spectrum β-lactamase-producing Escherichia coli and methicillin-resistant Staphylococcus aureus has caused a reduction in antibiotic effectiveness and an increase in mortality rates. Essential oils (EOs), known for their therapeutic efficacy, can be configured as novel broad-spectrum biocides. Accordingly, the bacteriostatic-bactericidal activity of Citrus Lemon (LEO), Pinus Sylvestris (PEO), Foeniculum Vulgaris (FEO), Ocimum Basilicum (BEO), Melissa Officinalis (MEO), Thymus Vulgaris (TEO), and Zingiber Officinalis Rosc. (GEO), at concentrations ranging from 1.25 to 40% (v/v), were tested in vitro against different E. coli and S. aureus strains using minimal inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs). The chemical compositions of the EOs were analyzed using GC/MS. The major components of all seven tested oils were limonene, α-pinene, anethole, estragole, citral, thymol, and zingiberene, respectively. We found that the bacteriostatic-bactericidal activity of the EOs was related to their chemotypes and concentrations, as well as the strain of the bacteria. A dose-effect correlation was found when testing GEO against S. aureus strains, whilst FEO was found to have no activity regardless of concentration. PEO, MEO, and BEO were found to have bactericidal effect with a MIC and MBC of 1.25% (v/v) against S. aureus strains, and LEO was found to have values of 1.25% (v/v) and 5% (v/v) against ATCC and clinical isolate, respectively. Interestingly, the antimicrobial activity of TEO was not related to oil concentration and the complete inhibition of growth across all E. coli and S. aureus was observed. Although preliminary, our data demonstrate the efficacy of EOs and pave the way for further investigations on their potential synergistic use with traditional drugs in the human and veterinary fields.Entities:
Keywords: Escherichia coli; GC-MS analysis; Staphylococcus aureus; antimicrobial activity; essential oils
Year: 2022 PMID: 35884233 PMCID: PMC9311876 DOI: 10.3390/antibiotics11070979
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Main components of tested Eos.
| N | Components | AI | LEO | PEO | FEO | BEO | MEO | TEO | GEO |
|---|---|---|---|---|---|---|---|---|---|
| % ± SEM | % ± SEM | % ± SEM | % ± SEM | % ± SEM | % ± SEM | % ± SEM | |||
| 1 | α-pinene a | 931 | 2.4 ± 0.5 | 29 ± 3 | 6.4 ± 0.9 | 0.34 ± 0.04 | 1.81 ± 0.10 | 1.73 ± 0.12 | |
| 2 | camphene a | 952 | 1.6 ± 0.3 | 0.12 ± 0.01 | 0.52 ± 0.05 | 1.89 ± 0.11 | 4.74 ± 0.27 | ||
| 3 | β-thujene | 968 | 1.94 ± 0.20 | 1.24 ± 0.23 | 0.20 ± 0.01 | 0.71 ± 0.06 | |||
| 4 | β-pinene a | 980 | 14.5 ± 1.0 | 17.2 ± 1.2 | 0.65 ± 0.07 | 0.65 ± 0.05 | 0.56 ± 0.03 | ||
| 5 | α-phellandrene a | 1003 | 5.2 ± 0.6 | 0.15 ± 0.01 | 4.4 ± 0.6 | ||||
| 6 | 3-carene a | 1016 | 13.1 ± 2.5 | ||||||
| 7 | o-cymene | 1021 | 1.1 ± 0.8 | 1 ± 0.1 | 19.6 ± 1.5 | ||||
| 8 | eucalyptol a | 1023 | 0.29 ± 0.02 | 1.2 ± 0.5 | 0.89 ± 0.05 | 1.9 ± 0.4 | |||
| 9 | limonene a | 1032 | 53 ± 5 | 9.8 ± 1.2 | 5.1 ± 1 | 4.3 ± 1 | 0.60 ± 0.04 | ||
| 10 | γ-terpinene a | 1064 | 5.9 ± 1.0 | 0.15 ± 0.02 | 9 ± 1 | ||||
| 11 | β-linalool a | 1101 | 0.21 ± 0.02 | 17 ± 2.6 | 0.96 ± 0.25 | 4 ± 1 | |||
| 12 | endo-borneol a | 1167 | 1.8 ± 0.7 | 1.01 ± 0.12 | |||||
| 13 | estragole a | 1198 | 1.5 ± 0.1 | 73 ± 6 | |||||
| 14 | citral a | 1240 | 3.8 ± 0.9 | 1.1 ± 0.08 | 43 ± 3 | ||||
| 15 | geraniol | 1254 | 2 ± 1 | ||||||
| 16 | anethole a | 1284 | 58.7 ± 3.9 | ||||||
| 17 | bornylacetate a | 1289 | 5.7 ± 1.3 | ||||||
| 18 | thymol a | 1290 | 47 ± 3 | ||||||
| 19 | geranyl aceate | 1385 | 0.87 ± 0.06 | 1.95 ± 0.10 | |||||
| 20 | caryophyllene a | 1415 | 0.136 ± 0.012 | 4.9 ± 0.9 | 0.43 ± 0.02 | 25 ± 1 | 2.2 ± 0.9 | ||
| 21 | α-bergamotene | 1430 | 0.212 ± 0.020 | 0.105 ± 0.012 | 3.2 ± 0.4 | 0.14 ± 0.01 | |||
| 22 | humulene | 1451 | 0.47 ± 0.02 | 0.237 ± 0.023 | 4.4 ± 0.9 | ||||
| 23 | α-curcumene a | 1481 | 15 ± 1 | ||||||
| 24 | zingiberene a | 1493 | 32.1 ± 1.8 | ||||||
| 25 | β-sesquiphellandrene a | 1521 | 11 ± 1 | ||||||
| 26 | caryophylleneoxyde | 1592 | 0.31 ± 0.05 | 1.68 ± 0.29 | 0.223 ± 0.012 | 2.2 ± 0.9 | 0.58 ± 0.03 |
a: Standard compounds. Arithmetic index (AI) was taken from Adams (2007) [17,18] and/or the NIST 2017 database. % ± SEM: relative percentage values of main compounds are means of three determinations with structural equation modeling (SEM) in all cases below 10%. Acronyms: LEO: Citrus Lemon; PEO: Pinus Sylvestris; FEO: Feoniculum Vulgare; BEO: Ocimum Basilicum; MEO: Melissa Officinalis; TEO: Thymus Vulgaris; GEO: Zingiber Officinalis Rosc.
Bacterial growth reduction rate, expressed as log10 CFU/mL compared to positive control, based on different EO concentrations. (a) E. coli ATCC growth reduction rate; (b) E. coli clinical isolate 462/20 reduction rate; (c) S. aureus ATCC reduction rate; (d) S. aureus clinical isolate 463/20 reduction rate. Acronyms: EO: Essential Oil; LEO: Citrus Lemon; PEO: Pinus Sylvestris; FEO: Feoniculum Vulgare; BEO: Ocimum Basilicum; MEO: Melissa Officinalis; TEO: Thymus Vulgaris; GEO: Zingiber Officinalis Rosc.; *: CFU/mL; n.g.: no growth; n.i. = no inhibition.
| (a) | |||||||
|---|---|---|---|---|---|---|---|
| EO | LEO * | PEO * | FEO * | BEO * | MEO * | TEO * | GEO * |
|
| 1011 | 1011 | 107 | 1012 | 1011 | n.g. | 108 |
|
| 108 | 1011 | 107 | 1012 | 1011 | n.g. | 108 |
|
| 104 | 109 | 107 | 1011 | 1011 | n.g. | 108 |
|
| 104 | 108 | 107 | 108 | 108 | n.g. | 108 |
|
| 103 | 108 | 104 | 108 | 109 | n.g. | 107 |
|
| 101 | 104 | 104 | 108 | 109 | n.g. | 106 |
| ( | |||||||
|
|
|
|
|
|
|
|
|
|
| 108 | 1010 | 109 | 107 | 109 | n.g. | 106 |
|
| 108 | 1010 | 107 | 107 | 107 | n.g. | 105 |
|
| 105 | 109 | 105 | 105 | 107 | n.g. | 105 |
|
| 105 | 108 | 105 | 105 | 107 | n.g. | 105 |
|
| 103 | 107 | 105 | 102 | 104 | n.g. | 104 |
|
| 101 | 106 | 104 | n.i. | 103 | n.g. | 101 |
| ( | |||||||
|
|
|
|
|
|
|
|
|
|
| n.g. | n.g. | n.i. | n.g. | n.g. | n.g. | 1011 |
|
| n.g. | n.g. | n.i. | n.g. | n.g. | n.g. | 1011 |
|
| n.g. | n.g. | n.i. | n.g. | n.g. | n.g. | 1011 |
|
| n.g. | n.g. | n.i. | n.g. | n.g. | n.g. | 1013 |
|
| n.g. | n.g. | n.i. | n.g. | n.g. | n.g. | 1014 |
|
| n.g. | 102 | n.i. | n.g. | n.g. | n.g. | 1014 |
| ( | |||||||
|
|
|
|
|
|
|
|
|
|
| n.g. | n.g. | n.i. | n.g. | n.g. | n.g. | 1012 |
|
| n.g. | n.g. | n.i. | n.g. | n.g. | n.g. | 1012 |
|
| n.g. | n.g. | n.i. | n.g. | n.g. | n.g. | 1012 |
|
| n.g. | n.g. | n.i. | n.g. | n.g. | n.g. | 1013 |
|
| 1012 | n.g. | n.i. | n.g. | n.g. | n.g. | 1014 |
|
| 1013 | 102 | n.i. | n.g. | n.g. | n.g. | 1014 |
Figure 1Bacterial growth of the tested strains. Response of bacterial strains in MH broth with varying percentages (v/v) of different EOs after 24 h of incubation, expressed as the rate of growth reduction in CFU/mL compared to positive controls. *: statistically significant dose–effect correlation (a) E. coli ATCC; (b) E. coli clinical isolate 462/20; (c) S. aureus ATCC; (d) S. aureus clinical isolate 463/20.